Gossamer Bio Inc (GOSS) Stock News

The Schall Law Firm is seeking investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its Phase 3 PROSERA study design, specifically concealing adverse facts about placebo response controls at certain testing sites.

A securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design and patient recruitment despite knowing of significant placebo effects, particularly at Latin American sites.

Rosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.

A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo response controls at Latin American testing sites, causing investors to purchase securities at artificially inflated prices. Investors who purchased shares between June 16, 2025, and February 20, 2026, have until June 1, 2026, to apply as lead plaintiff.

Rosen Law Firm is notifying investors in Gossamer Bio, Inc., FS KKR Capital Corp., and Regencell Bioscience Holdings Limited of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the June 1, 2026 deadline. The Gossamer case alleges defendants made false statements about their Phase 3 PROSERA study design while concealing material adverse facts.

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.

Rosen Law Firm is encouraging investors who purchased securities in Gossamer Bio, Upstart Holdings, and FS KKR Capital Corp. during specified periods to join class action lawsuits. The firm is seeking a lead plaintiff for the Gossamer case by June 1, 2026, with allegations involving false statements regarding a Phase 3 clinical study.

Pomerantz Law Firm has filed class action lawsuits against Gossamer Bio, Inc. and other companies for alleged securities fraud. Gossamer's stock plummeted 80.13% on February 23, 2026, after its Phase 3 PROSERA study for seralutinib failed to meet its primary endpoint for treating pulmonary arterial hypertension. Investors with losses are urged to contact the firm by the June 1, 2026 deadline to potentially become lead plaintiffs.

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price decline. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Gossamer Bio, Inc., where defendants allegedly made false statements about their Phase 3 PROSERA study design, particularly regarding placebo response controls at Latin American testing sites. Investors who purchased securities during the Class Period (June 16, 2025 - February 20, 2026) may be eligible for compensation. The lead plaintiff deadline is June 1, 2026.

Gossamer Bio (GOSS) shares plummeted over 80% on February 23, 2026, after the company disclosed that its Phase 3 PROSERA trial failed to meet its primary endpoint. A securities class action lawsuit has been filed alleging the company and its CEO made materially misleading statements about the trial design while concealing enrollment risks at Latin American sites. Investors who purchased GOSS securities between June 16, 2025 and February 20, 2026 can seek appointment as lead plaintiff by the June 1, 2026 deadline.

Rosen Law Firm is reminding investors in Gossamer Bio, ImmunityBio, and Immutep Ltd. about upcoming deadlines to join securities class action lawsuits. The lawsuits allege that defendants made false and misleading statements to investors, with Gossamer Bio specifically accused of concealing material adverse facts concerning its Phase 3 PROSERA study design. Investors who purchased securities during specified class periods may be eligible for compensation.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Pinterest (PINS), New Era Energy & Digital (NUAI), Gossamer Bio (GOSS), and Medpace Holdings (MEDP). The lawsuits allege that defendants made false or misleading statements regarding business operations, financial performance, and prospects. Investors have until late May to early June 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing material adverse facts about study design, particularly regarding placebo response control at Latin American testing sites. Investors who purchased securities between June 16, 2025, and February 20, 2026, may be eligible to participate in the lawsuit.

Rosen Law Firm is notifying investors in Gossamer Bio, Inc. (NASDAQ: GOSS) of a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding the Phase 3 PROSERA study design, particularly concerning placebo response controls at Latin American testing sites. Investors who purchased securities between June 16, 2025 and February 20, 2026 may be eligible for compensation. The lead plaintiff deadline is June 1, 2026.

Rosen Law Firm has filed class action lawsuits against Gossamer Bio, Inc. (GOSS), zSpace Inc. (ZSPC), and is investigating claims against PennyMac Financial Services, Inc. (PFSI). The Gossamer lawsuit alleges defendants made false statements about their Phase 3 PROSERA study design, particularly regarding placebo response controls at Latin American testing sites. Investors who purchased securities